Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.12.10.20246827: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our results should be interpreted within the context of study limitations. We assumed that the efficacy of a vaccine would be reduced by 10-50% in comorbid and elderly individuals, based on estimated reductions for influenza vaccine efficacy (37). If vaccination performed equally well in comorbid individuals, we would expect a higher reduction for adverse clinical outcomes. We did not consider drop out over the course of the vaccination …
SciScore for 10.1101/2020.12.10.20246827: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our results should be interpreted within the context of study limitations. We assumed that the efficacy of a vaccine would be reduced by 10-50% in comorbid and elderly individuals, based on estimated reductions for influenza vaccine efficacy (37). If vaccination performed equally well in comorbid individuals, we would expect a higher reduction for adverse clinical outcomes. We did not consider drop out over the course of the vaccination program, which would affect the level of protection conferred by vaccination. Finally, we did not consider children under 18 years of age for vaccination in these scenarios. Phase III trials are mainly performed in adults and it may be several months before trial results in children are available to support vaccination programs in this population. This study indicates that, while vaccination could significantly mitigate the severity of outbreaks, it is unlikely to eliminate the need for other non-pharmaceutical interventions before reaching a sufficiently high level of population immunity. Nevertheless, our results show that vaccination is a key public health measure in the fight against COVID-19.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
